Targeting epigenetic modifications for the treatment and prevention of breast cancer

Bhuvaneswari Ramaswamy, Joseph A. Sparano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

DNA methylation, histone modification, and nucleosome remodeling are the three intercalated events that result in epigenetic modification, which in turn alters gene expression. Aberrant epigenetic regulation resulting in altered gene expression has been clearly implicated in the initiation and progression of breast cancer. Our understanding of the landscape of these changes in breast cancer has increased tremendously over the past decade. Significant advancement has been made in the preclinical arena to identify targets that are epigenetically altered in breast cancer and to modulate these targets with epigenetic therapies to improve tumor response. Clinical translation of these concepts is currently ongoing and shows promise in improving outcomes in breast cancer. This article provides a comprehensive review of the completed and ongoing clinical trials of epigenetic therapy in the management and prevention of breast cancer and the rationale leading to the design of these trials.

Original languageEnglish (US)
Pages (from-to)198-207
Number of pages10
JournalCurrent Breast Cancer Reports
Volume2
Issue number4
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Epigenomics
Breast Neoplasms
Histone Code
Gene Expression
Nucleosomes
DNA Methylation
Clinical Trials
Therapeutics
Neoplasms

Keywords

  • Breast cancer
  • Demethylating agents
  • Epigenetic targets
  • Histone deacetylase inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting epigenetic modifications for the treatment and prevention of breast cancer. / Ramaswamy, Bhuvaneswari; Sparano, Joseph A.

In: Current Breast Cancer Reports, Vol. 2, No. 4, 12.2010, p. 198-207.

Research output: Contribution to journalArticle

@article{a1331c70257242daa9156cd61bc55e54,
title = "Targeting epigenetic modifications for the treatment and prevention of breast cancer",
abstract = "DNA methylation, histone modification, and nucleosome remodeling are the three intercalated events that result in epigenetic modification, which in turn alters gene expression. Aberrant epigenetic regulation resulting in altered gene expression has been clearly implicated in the initiation and progression of breast cancer. Our understanding of the landscape of these changes in breast cancer has increased tremendously over the past decade. Significant advancement has been made in the preclinical arena to identify targets that are epigenetically altered in breast cancer and to modulate these targets with epigenetic therapies to improve tumor response. Clinical translation of these concepts is currently ongoing and shows promise in improving outcomes in breast cancer. This article provides a comprehensive review of the completed and ongoing clinical trials of epigenetic therapy in the management and prevention of breast cancer and the rationale leading to the design of these trials.",
keywords = "Breast cancer, Demethylating agents, Epigenetic targets, Histone deacetylase inhibitors",
author = "Bhuvaneswari Ramaswamy and Sparano, {Joseph A.}",
year = "2010",
month = "12",
doi = "10.1007/s12609-010-0027-z",
language = "English (US)",
volume = "2",
pages = "198--207",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting epigenetic modifications for the treatment and prevention of breast cancer

AU - Ramaswamy, Bhuvaneswari

AU - Sparano, Joseph A.

PY - 2010/12

Y1 - 2010/12

N2 - DNA methylation, histone modification, and nucleosome remodeling are the three intercalated events that result in epigenetic modification, which in turn alters gene expression. Aberrant epigenetic regulation resulting in altered gene expression has been clearly implicated in the initiation and progression of breast cancer. Our understanding of the landscape of these changes in breast cancer has increased tremendously over the past decade. Significant advancement has been made in the preclinical arena to identify targets that are epigenetically altered in breast cancer and to modulate these targets with epigenetic therapies to improve tumor response. Clinical translation of these concepts is currently ongoing and shows promise in improving outcomes in breast cancer. This article provides a comprehensive review of the completed and ongoing clinical trials of epigenetic therapy in the management and prevention of breast cancer and the rationale leading to the design of these trials.

AB - DNA methylation, histone modification, and nucleosome remodeling are the three intercalated events that result in epigenetic modification, which in turn alters gene expression. Aberrant epigenetic regulation resulting in altered gene expression has been clearly implicated in the initiation and progression of breast cancer. Our understanding of the landscape of these changes in breast cancer has increased tremendously over the past decade. Significant advancement has been made in the preclinical arena to identify targets that are epigenetically altered in breast cancer and to modulate these targets with epigenetic therapies to improve tumor response. Clinical translation of these concepts is currently ongoing and shows promise in improving outcomes in breast cancer. This article provides a comprehensive review of the completed and ongoing clinical trials of epigenetic therapy in the management and prevention of breast cancer and the rationale leading to the design of these trials.

KW - Breast cancer

KW - Demethylating agents

KW - Epigenetic targets

KW - Histone deacetylase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=78149470862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149470862&partnerID=8YFLogxK

U2 - 10.1007/s12609-010-0027-z

DO - 10.1007/s12609-010-0027-z

M3 - Article

VL - 2

SP - 198

EP - 207

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 4

ER -